BioSpace

Praxis Ends Epilepsy Study Early Due to Strong Results, Heads to FDA

Praxis has also announced a “successful” pre-NDA meeting with the FDA for its essential tremor drug candidate ulixacaltamide, ...

Praxis' Epilepsy Drug Too Good To Continue, FDA Meeting Up Next

Praxis Precision stock rallies on positive EMBOLD results, FDA meeting confirmed, and analyst increases probability of ...
Investor's Business Daily on MSN

Praxis surges 30%, hitting another 3-year high on a surprise win in epilepsy

Praxis Precision Medicines shares shot skyward Friday after the company stopped an epilepsy study early due to strong ...

Praxis Completes FDA Meeting for Tremor Treatment, Reports Positive Results for Epilepsy Drug

Praxis Precision Medicine said it had completed its pre-new drug application meeting with the Food and Drug Administration for its essential tremor treatment. The company said Thursday it expects to ...
Reuters

UCB says Keppra XR epilepsy drug approved in U.S.

BRUSSELS (Reuters) - Belgian pharma group UCB said on Monday that U.S. health authorities had approved epilepsy drug Keppra XR and that it would go on sale just before its mother drug loses patent ...
Medscape

FDA Warns of Potentially Lethal Reaction to Seizure Meds

The antiseizure drugs levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam, generic) and clobazam (Onfi, Sympazan, generic) can cause a rare but serious drug hypersensitivity reaction that can be ...